12 June 2019
Avacta Group plc
("Avacta", the "Company" or the "Group")
Avacta's Chief Scientific Officer to Present at Major US Conference
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and reagents, is pleased to announce that its Chief Scientific Officer, Dr Amrik Basran, will be presenting at the Next Generation Protein Therapeutics & Bioconjugates conference in San Francisco, California on 19 June 2019.
Dr Basran's presentation, 'Affimer Therapeutics: A Novel Human Scaffold for the Generation of Bi-specific Molecules', will give an overview of the benefits of using Affimer technology to generate bispecific drug molecules.
Bispecific therapy - single molecules that engage with two drug targets simultaneously - is a major area of focus in large pharma immuno-oncology programmes. Avacta has highlighted bispecifics as a key element of its therapeutic pipeline strategy, alongside the development of its novel tumour microenvironment activated drug conjugates.
Dr Basran's presentation will highlight the stability, solubility and ease of manufacturing functional Affimer bispecifics incorporating Avacta's proprietary serum half-life extension technology (Affimer XTTM), as well as PD-L1 and LAG-3 Affimer inhibitors.
- Ends -
For further information from Avacta Group plc, please contact:
Avacta Group plc
Alastair Smith, Chief Executive Officer
Tony Gardiner, Chief Financial Officer
Tel: +44 (0) 844 414 0452
finnCap Ltd (Nominated Adviser and Joint Broker)
Geoff Nash / Giles Rolls - Corporate Finance
Tim Redfern - ECM
WG Partners (Joint Broker)
Nigel Birks / Nigel Barnes
David Wilson / Claes Spang
Tel: +44 (0) 207 220 0500
Tel: +44 (0) 203 705 9318
Tel: +44 (0) 203 705 9217
Turner Pope Investments
James Pope / Ben Turner
Yellow Jersey PR (Financial Media and IR)
Zyme Communications (Trade and Regional Media)
Tel: +44 (0) 203 621 4120
Tel: +44 (0)7764 947 137
Tel: +44 (0)7544 275 882
Tel: +44 (0)7787 502 947
About Avacta Group plc - www.avacta.com
Avacta's principal focus is on its proprietary Affimer® technology which is a novel engineered alternative to antibodies that has wide application in Life Sciences for diagnostics, therapeutics and general research and development.
Antibodies dominate markets worth in excess of $100bn despite their shortcomings. Affimer technology has been designed to address many of these negative performance issues, principally; the time taken to generate new antibodies, the reliance on an animal's immune response, poor specificity in many cases, and batch to batch variability. Affimer technology is based on a small protein that can be quickly generated to bind with high specificity and affinity to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an in-house focus on immuno-oncology as well as partnered development programmes. Avacta is commercialising non-therapeutic Affimer reagents through licensing to developers of life sciences research tools and diagnostics.
To register for news alerts by email go to www.avacta.com/investor-news-email-alerts
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.